Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H36O2 |
Molecular Weight | 308.4986 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC
InChI
InChIKey=FMMOOAYVCKXGMF-MURFETPASA-N
InChI=1S/C20H36O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22-4-2/h8-9,11-12H,3-7,10,13-19H2,1-2H3/b9-8-,12-11-
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24508058Curator's Comment: description was created based on several sources, including http://www.google.ru/patents/US3198704
https://www.ncbi.nlm.nih.gov/pubmed/5984527
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24508058
Curator's Comment: description was created based on several sources, including http://www.google.ru/patents/US3198704
https://www.ncbi.nlm.nih.gov/pubmed/5984527
Ethyl linoleate (ELA) is an essential fatty acid used in many cosmetics for its anti-inflammatory properties. It inhibits the action of the reactive species of oxygen released by neutrophils due to an excess of bacteria, and prevents the hyperkeratinization induced by a lack of linoleic acid. Though there are few reports stating the antiinflammatory activity of ELA, the mechanism by which ELA exhibits anti-inflammatory activity remains unclear. An aqueous emulsion of ethyl linoleate can be used as parenteral injection for curring ailments where a high plasma-cholesterol level of the blood is indicated. Improvements in liver function tests during the administration of ELA were noticed in almost all cases with a few aggravated exceptions. The administration of ELA can expect the satisfactory response to the patients both with liver cirrhosis and with chronic hepatitis.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5928125
Curator's Comment: Ethyl linoleate (Mandenole), an ethyl ester of linoleic acid in a 10 per cent aqueous emulsion, was developed by Mr. K. N. Roy, of Messrs. Martin and Harris Private Ltd
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0032306 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24508058 |
3.7 µM [IC50] | ||
Target ID: GO:0002537 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24508058 |
3.4 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Ethyl linoleate as an antiatherogenic agent. An experimental study in rabbits. | 1966 Oct |
|
Antimicrobial activity of n-6, n-7 and n-9 fatty acids and their esters for oral microorganisms. | 2010 Aug |
|
Salicylic acid peel incorporating triethyl citrate and ethyl linoleate in the treatment of moderate acne: a new therapeutic approach. | 2013 Aug |
|
Chinese yam extracts containing β-sitosterol and ethyl linoleate protect against atherosclerosis in apolipoprotein E-deficient mice and inhibit muscular expression of VCAM-1 in vitro. | 2014 Apr |
|
Ethyl linoleate from garlic attenuates lipopolysaccharide-induced pro-inflammatory cytokine production by inducing heme oxygenase-1 in RAW264.7 cells. | 2014 Apr |
Patents
Sample Use Guides
1.8 g/day for 28 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24508058
The effect of Ethyl linoleate (ELA) on p38, ERK1/2, JNK, and Akt activation was examined in LPS-stimulated RAW 264.7 cells. The activation of MAPKs was recorded after 15 min of treatment with LPS (1 μg/mL). When the cells were pretreated with ELA at the indicated concentrations for 1 h, followed by stimulation with 1 μg/mL LPS for 15 min, they showed an ELA dose-dependent decrease in phosphorylation of ERK1/2, JNK, p38, and Akt as compared to cells treated with LPS alone. These data suggest that ELA significantly suppressed the LPS-induced activation of ERK1/2, JNK, p38, and Akt in RAW 264.7 cells
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
1879 (Number of products:1)
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000078992
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | |||
|
DTXSID1060269
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | |||
|
208-868-4
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | |||
|
5282184
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | |||
|
MJ2YTT4J8M
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | |||
|
24522
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | RxNorm | ||
|
31572
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | |||
|
SUB13745MIG
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | |||
|
544-35-4
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | |||
|
50447
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106238
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | |||
|
1265843
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | |||
|
MJ2YTT4J8M
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | |||
|
m5145
Created by
admin on Fri Dec 15 14:58:59 GMT 2023 , Edited by admin on Fri Dec 15 14:58:59 GMT 2023
|
PRIMARY | Merck Index |
SUBSTANCE RECORD